Loading clinical trials...
Loading clinical trials...
Phase 4, Open-label Study to Evaluate Treatment Satisfaction With Erenumab in Patients With Migraine
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
Rehabilitation and Neurological Services LLC
Huntsville, Alabama, United States
Elite Clinical Studies LLC
Phoenix, Arizona, United States
Neurology Center of North Orange County
Fullerton, California, United States
The Neurology Group
Pomona, California, United States
Mountain Neurological Research Center
Basalt, Colorado, United States
Mindscapes Counseling, LLC
Norwich, Connecticut, United States
Reliable Clinical Research, LLC
Hialeah, Florida, United States
Homestead Associates In Research Inc
Homestead, Florida, United States
New Age Medical Research Corporation
Miami, Florida, United States
The Community Research of South Florida
Miami Lakes, Florida, United States
Start Date
June 11, 2021
Primary Completion Date
September 28, 2023
Completion Date
September 28, 2023
Last Updated
September 19, 2024
240
ACTUAL participants
Erenumab
DRUG
Lead Sponsor
Amgen
NCT07018713
NCT06641466
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions